Relay Therapeutics, Inc. (RLAY) stock
RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$17.27−0.82 (-4.53%)
Close on Nov 16, 2026Market cap $3.78BP/E –Yield –
Relay Therapeutics cash
Cash and short-term investments held at the end of each period.
Relay Therapeutics's cash was $121.19M at Jun 30, 2026. For fiscal 2025 it was $84.02M, down 33.5% from the year before. The highest annual figure on record is $448.52M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.02M | -33.5% |
| FY2024 | Dec 31, 2024 | $126.41M | -13.7% |
| FY2023 | Dec 31, 2023 | $146.44M | -5.1% |
| FY2022 | Dec 31, 2022 | $154.37M | -45.4% |
| FY2021 | Dec 31, 2021 | $282.70M | -37.0% |
| FY2020 | Dec 31, 2020 | $448.52M | +947.2% |
| FY2019 | Dec 31, 2019 | $42.83M | -89.9% |
| FY2018 | Dec 31, 2018 | $422.38M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $121.19M | +6.4% |
| Q1 FY2026 | Mar 31, 2026 | $204.59M | +118.7% |
| Q4 FY2025 | Dec 31, 2025 | $84.02M | -33.5% |
| Q3 FY2025 | Sep 30, 2025 | $91.56M | -39.9% |
| Q2 FY2025 | Jun 30, 2025 | $113.94M | -15.0% |
| Q1 FY2025 | Mar 31, 2025 | $93.54M | -38.8% |
| Q4 FY2024 | Dec 31, 2024 | $126.41M | -13.7% |
| Q3 FY2024 | Sep 30, 2024 | $152.36M | +0.7% |
| Q2 FY2024 | Jun 30, 2024 | $134.13M | -8.1% |
| Q1 FY2024 | Mar 31, 2024 | $152.87M | -5.2% |
| Q4 FY2023 | Dec 31, 2023 | $146.44M | -5.1% |
| Q3 FY2023 | Sep 30, 2023 | $151.33M | -57.3% |
| Q2 FY2023 | Jun 30, 2023 | $145.90M | +35.4% |
| Q1 FY2023 | Mar 31, 2023 | $161.28M | +35.0% |
| Q4 FY2022 | Dec 31, 2022 | $154.37M | -45.4% |
| Q3 FY2022 | Sep 30, 2022 | $354.64M | +55.2% |
| Q2 FY2022 | Jun 30, 2022 | $107.74M | -58.6% |
| Q1 FY2022 | Mar 31, 2022 | $119.45M | -54.5% |
| Q4 FY2021 | Dec 31, 2021 | $282.70M | -37.0% |
| Q3 FY2021 | Sep 30, 2021 | $228.56M | -59.1% |
| Q2 FY2021 | Jun 30, 2021 | $260.07M | +89.8% |
| Q1 FY2021 | Mar 31, 2021 | $262.72M | +273.5% |
| Q4 FY2020 | Dec 31, 2020 | $448.52M | +947.2% |
| Q3 FY2020 | Sep 30, 2020 | $559.28M | +1825.6% |
| Q2 FY2020 | Jun 30, 2020 | $137.05M | +248.2% |
| Q1 FY2020 | Mar 31, 2020 | $70.34M | -83.3% |
| Q4 FY2019 | Dec 31, 2019 | $42.83M | – |
| Q3 FY2019 | Sep 30, 2019 | $29.05M | – |
| Q2 FY2019 | Jun 30, 2019 | $39.36M | – |
| Q4 FY2018 | Dec 31, 2018 | $422.38M | – |
See a number that looks wrong?